Investors in Pharmaceutical

M Ventures is the strategic corporate venture capital fund of Merck KGaA, Darmstadt, Germany. Established in 2009, it manages a fund of €600 million, investing in biotechnology and technology sectors. The fund focuses on healthcare drug development, life science tools, electronics, and frontier technology and sustainability. M Ventures aims to support visionary companies that develop innovative solutions for treating diseases, advancing scientific research, and addressing sustainability challenges. They take an active role in their portfolio companies, collaborating closely with entrepreneurs and co-investors.

Meneldor offers her customers the unique opportunity to co-invest alongside specialists, in exciting early stage Biotech and Pharma companies. A sector often considered as very risky and highly complex. Meneldor thoroughly studies the science behind her potential portfolio companies. If the science is sound, then all other key aspects; IP, medical need, addressable markets, competition, risk, management, financial needs, valuation, etc., are assessed. Only if a target company meets our selection criteria, Meneldor will invest and invite her co-investors to participate.

HTL Innovations provides a seed funding support and a minority financial support. HTL Biotechnology is a French biotech and a world leader in the development and responsible bioproduction of pharmaceutical-grade biopolymers (Hyaluronic acid, polynucleotides). These biopolymers are used by healthcare companies for the development of treatments in various cutting-edge therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology.HTL Innovations

Athenion are business incubators and investment companies that focus on the development and distribution of high-quality products for the pharmaceutical market and the healthcare industry. The founders of the company bring with them education and experience in various disciplines. The companies of the Athenion Group are headed by a management team consisting of specialists in science, business and finance who have the knowledge and experience to turn an innovation into a successful product.

Bayer G4A is a healthcare accelerator that offers investment, mentoring, and networking opportunities for startups and developers. G4A is Bayer’s digital health partnerships and investments team dedicated to scaling digital health. Our team’s vision is to reach health for all through digital health.

The cluster organisation for Catalonia's healthcare and life sciences sector. Biocat is the institution that promotes the life sciences and healthcare ecosystem in Catalonia and works to maximize its economic and social impact. Biocat’s strategy focuses on positioning the BioRegion of Catalonia as one of the leading European hubs, offering researchers and professionals innovative capacity with programs to improve talent and entrepreneurship, accelerating technology transfer and business growth by supporting TTOs and startups, and helping attract investors and investment to the ecosystem.

VITA Accelerator is the Digital Health Accelerator of CDP National Accelerators Network, born from the initiative of CDP Venture Capital SGR together with Healthware Group and Accelerace.We are glad to announce the launch of a novel Program, aimed to support startups based in Italy or interested in expanding to Italy.

We scale start-ups. We are now looking for our next cohort of remarkable start-ups to join our new programme called The Health Hub, built together with our partner Novartis, one of the leading pharma companies in the world. Our focus is on how Health Tech can be used to drastically innovate long-term disease management.

DayOne supports promising ventures that combine groundbreaking technologies, healthcare expertise and entrepreneurial spirit. At DayOne, we are shaping the future of health by accelerating digital transformation in Europe’s leading healthcare and life sciences hub. As the Healthcare Innovation initiative by Basel Area Business & Innovation, DayOne believes in a patient-centric and sustainable approach to healthcare.

ODI Startup Accelerator is a year-long, bespoke programme for data-oriented startups. The ODI is a non-profit company, founded in 2012 by inventor of the web, Sir Tim Berners-Lee, and AI expert, Sir Nigel Shadbolt, and headquartered in King’s Cross, London, UK. Our mission is to work with companies and governments to build an open, trustworthy data ecosystem.

Development Capital, founded in 2013, provides €2-12 million in growth capital to Irish SMEs, focusing on export markets. With €100 million invested in 12 companies, they offer flexible investment structures and take minority stakes to support growth strategies like expansion, acquisitions, and management buyouts. They prioritize responsible investing by integrating ESG considerations into their process.

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by great entrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success.